

Global CDMO Service for Peptide APIs Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G990641EC9C2EN.html>

Date: June 2026

Pages: 161

Price: US\$ 4,480.00 (Single User License)

ID: G990641EC9C2EN

Abstracts

The global CDMO Service for Peptide APIs market size is expected to reach \$ 13270 million by 2032, rising at a market growth of 18.2% CAGR during the forecast period (2026-2032).

CDMO Service for Peptide APIs refers to integrated outsourced services covering process development, analytical development, quality studies, technology transfer, scale-up, GMP manufacturing, and commercial supply for therapeutic peptide active pharmaceutical ingredients, with peptide drug substances and related intermediates, rather than finished dosage forms, as the main deliverables. The upstream supply chain mainly includes protected amino acids, specialty amino acids, resin supports, coupling reagents, cleavage and deprotection reagents, organic solvents, purification media, analytical consumables, and packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotechnology firms, specialty generic drug developers, and drug manufacturers that further formulate peptide APIs into injectables, lyophilized products, or other dosage forms. Competitive strength in this segment is typically reflected in process development capability, impurity control, quality system maturity, scale-up efficiency, and reliability of commercial supply. The global gross margin of CDMO Service for Peptide APIs in 2025 is estimated at 25%-40%.

This report studies the global CDMO Service for Peptide APIs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for CDMO Service for Peptide APIs, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of CDMO Service for Peptide

APIs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global CDMO Service for Peptide APIs total market, 2021-2032, (USD Million)

Global CDMO Service for Peptide APIs total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: CDMO Service for Peptide APIs total market, key domestic companies, and share, (USD Million)

Global CDMO Service for Peptide APIs revenue by player, revenue and market share 2021-2026, (USD Million)

Global CDMO Service for Peptide APIs total market by Type, CAGR, 2021-2032, (USD Million)

Global CDMO Service for Peptide APIs total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global CDMO Service for Peptide APIs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include PolyPeptide, Bachem, AmbioPharm, CordenPharma, CPC Scientific, Piramal Pharma Solutions, Almac Group, Aspen API, Neuland Laboratories, USV, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world CDMO Service for Peptide APIs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global CDMO Service for Peptide APIs Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global CDMO Service for Peptide APIs Market, Segmentation by Type:

GMP Services

Non-GMP Services

Global CDMO Service for Peptide APIs Market, Segmentation by Synthesis Technology:

SPPS

LPPS

Hybrid Technology

Global CDMO Service for Peptide APIs Market, Segmentation by Application:

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Institutions

Others

Companies Profiled:

PolyPeptide

Bachem

AmbioPharm

CordenPharma

CPC Scientific

Piramal Pharma Solutions

Almac Group

Aspen API

Neuland Laboratories

USV

Aurigene Pharmaceutical Services

PeptiStar

BCN Peptides

Creative Peptides

Space Peptides

Cambrex

Nippon Shokubai

ScinoPharm

ChengDu ShengNuo Biotec

WuXi TIDES

Asymchem

Medtide

Jiuzhou Pharma

Hybio Pharmaceutical

JYMed Peptide

Key Questions Answered

1. How big is the global CDMO Service for Peptide APIs market?
2. What is the demand of the global CDMO Service for Peptide APIs market?
3. What is the year over year growth of the global CDMO Service for Peptide APIs market?
4. What is the total value of the global CDMO Service for Peptide APIs market?
5. Who are the Major Players in the global CDMO Service for Peptide APIs market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 CDMO Service for Peptide APIs Introduction
- 1.2 World CDMO Service for Peptide APIs Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World CDMO Service for Peptide APIs Total Market by Region (by Headquarter Location)
 - 1.3.1 World CDMO Service for Peptide APIs Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.3 China Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.4 Europe Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.5 Japan Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.6 South Korea Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
 - 1.3.8 India Based Company CDMO Service for Peptide APIs Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 CDMO Service for Peptide APIs Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.2 World CDMO Service for Peptide APIs Consumption Value by Region
 - 2.2.1 World CDMO Service for Peptide APIs Consumption Value by Region (2021-2026)
 - 2.2.2 World CDMO Service for Peptide APIs Consumption Value Forecast by Region (2027-2032)
- 2.3 United States CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.4 China CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.5 Europe CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.6 Japan CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.7 South Korea CDMO Service for Peptide APIs Consumption Value (2021-2032)
- 2.8 ASEAN CDMO Service for Peptide APIs Consumption Value (2021-2032)

2.9 India CDMO Service for Peptide APIs Consumption Value (2021-2032)

3 WORLD CDMO SERVICE FOR PEPTIDE APIS COMPANIES COMPETITIVE ANALYSIS

3.1 World CDMO Service for Peptide APIs Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global CDMO Service for Peptide APIs Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for CDMO Service for Peptide APIs in 2025

3.2.3 Global Concentration Ratios (CR8) for CDMO Service for Peptide APIs in 2025

3.3 CDMO Service for Peptide APIs Company Evaluation Quadrant

3.4 CDMO Service for Peptide APIs Market: Overall Company Footprint Analysis

3.4.1 CDMO Service for Peptide APIs Market: Region Footprint

3.4.2 CDMO Service for Peptide APIs Market: Company Product Type Footprint

3.4.3 CDMO Service for Peptide APIs Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: CDMO Service for Peptide APIs Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: CDMO Service for Peptide APIs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: CDMO Service for Peptide APIs Revenue Market Share Comparison (2021 & 2025 & 2032)

4.2 United States Based Companies VS China Based Companies: CDMO Service for Peptide APIs Consumption Value Comparison

4.2.1 United States VS China: CDMO Service for Peptide APIs Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: CDMO Service for Peptide APIs Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based CDMO Service for Peptide APIs Companies and Market Share, 2021-2026

4.3.1 United States Based CDMO Service for Peptide APIs Companies, Headquarters

(States, Country)

4.3.2 United States Based Companies CDMO Service for Peptide APIs Revenue, (2021-2026)

4.4 China Based Companies CDMO Service for Peptide APIs Revenue and Market Share, 2021-2026

4.4.1 China Based CDMO Service for Peptide APIs Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies CDMO Service for Peptide APIs Revenue, (2021-2026)

4.5 Rest of World Based CDMO Service for Peptide APIs Companies and Market Share, 2021-2026

4.5.1 Rest of World Based CDMO Service for Peptide APIs Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies CDMO Service for Peptide APIs Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World CDMO Service for Peptide APIs Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 GMP Services

5.2.2 Non-GMP Services

5.3 Market Segment by Type

5.3.1 World CDMO Service for Peptide APIs Market Size by Type (2021-2026)

5.3.2 World CDMO Service for Peptide APIs Market Size by Type (2027-2032)

5.3.3 World CDMO Service for Peptide APIs Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY SYNTHESIS TECHNOLOGY

6.1 World CDMO Service for Peptide APIs Market Size Overview by Synthesis Technology: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Synthesis Technology

6.2.1 SPPS

6.2.2 LPPS

6.2.3 Hybrid Technology

6.3 Market Segment by Synthesis Technology

6.3.1 World CDMO Service for Peptide APIs Market Size by Synthesis Technology (2021-2026)

6.3.2 World CDMO Service for Peptide APIs Market Size by Synthesis Technology (2027-2032)

6.3.3 World CDMO Service for Peptide APIs Market Size Market Share by Synthesis Technology (2027-2032)

7 MARKET ANALYSIS BY APPLICATION

7.1 World CDMO Service for Peptide APIs Market Size Overview by Application: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Application

7.2.1 Pharmaceutical Companies

7.2.2 Biotechnology Companies

7.2.3 Academic and Research Institutions

7.2.4 Others

7.3 Market Segment by Application

7.3.1 World CDMO Service for Peptide APIs Market Size by Application (2021-2026)

7.3.2 World CDMO Service for Peptide APIs Market Size by Application (2027-2032)

7.3.3 World CDMO Service for Peptide APIs Market Size Market Share by Application (2021-2032)

8 COMPANY PROFILES

8.1 PolyPeptide

8.1.1 PolyPeptide Details

8.1.2 PolyPeptide Major Business

8.1.3 PolyPeptide CDMO Service for Peptide APIs Product and Services

8.1.4 PolyPeptide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.1.5 PolyPeptide Recent Developments/Updates

8.1.6 PolyPeptide Competitive Strengths & Weaknesses

8.2 Bachem

8.2.1 Bachem Details

8.2.2 Bachem Major Business

8.2.3 Bachem CDMO Service for Peptide APIs Product and Services

8.2.4 Bachem CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.2.5 Bachem Recent Developments/Updates

8.2.6 Bachem Competitive Strengths & Weaknesses

8.3 AmbioPharm

- 8.3.1 AmbioPharm Details
- 8.3.2 AmbioPharm Major Business
- 8.3.3 AmbioPharm CDMO Service for Peptide APIs Product and Services
- 8.3.4 AmbioPharm CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
- 8.3.5 AmbioPharm Recent Developments/Updates
- 8.3.6 AmbioPharm Competitive Strengths & Weaknesses
- 8.4 CordenPharma
 - 8.4.1 CordenPharma Details
 - 8.4.2 CordenPharma Major Business
 - 8.4.3 CordenPharma CDMO Service for Peptide APIs Product and Services
 - 8.4.4 CordenPharma CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.4.5 CordenPharma Recent Developments/Updates
 - 8.4.6 CordenPharma Competitive Strengths & Weaknesses
- 8.5 CPC Scientific
 - 8.5.1 CPC Scientific Details
 - 8.5.2 CPC Scientific Major Business
 - 8.5.3 CPC Scientific CDMO Service for Peptide APIs Product and Services
 - 8.5.4 CPC Scientific CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.5.5 CPC Scientific Recent Developments/Updates
 - 8.5.6 CPC Scientific Competitive Strengths & Weaknesses
- 8.6 Piramal Pharma Solutions
 - 8.6.1 Piramal Pharma Solutions Details
 - 8.6.2 Piramal Pharma Solutions Major Business
 - 8.6.3 Piramal Pharma Solutions CDMO Service for Peptide APIs Product and Services
 - 8.6.4 Piramal Pharma Solutions CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.6.5 Piramal Pharma Solutions Recent Developments/Updates
 - 8.6.6 Piramal Pharma Solutions Competitive Strengths & Weaknesses
- 8.7 Almac Group
 - 8.7.1 Almac Group Details
 - 8.7.2 Almac Group Major Business
 - 8.7.3 Almac Group CDMO Service for Peptide APIs Product and Services
 - 8.7.4 Almac Group CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.7.5 Almac Group Recent Developments/Updates
 - 8.7.6 Almac Group Competitive Strengths & Weaknesses

8.8 Aspen API

8.8.1 Aspen API Details

8.8.2 Aspen API Major Business

8.8.3 Aspen API CDMO Service for Peptide APIs Product and Services

8.8.4 Aspen API CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.8.5 Aspen API Recent Developments/Updates

8.8.6 Aspen API Competitive Strengths & Weaknesses

8.9 Neuland Laboratories

8.9.1 Neuland Laboratories Details

8.9.2 Neuland Laboratories Major Business

8.9.3 Neuland Laboratories CDMO Service for Peptide APIs Product and Services

8.9.4 Neuland Laboratories CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.9.5 Neuland Laboratories Recent Developments/Updates

8.9.6 Neuland Laboratories Competitive Strengths & Weaknesses

8.10 USV

8.10.1 USV Details

8.10.2 USV Major Business

8.10.3 USV CDMO Service for Peptide APIs Product and Services

8.10.4 USV CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.10.5 USV Recent Developments/Updates

8.10.6 USV Competitive Strengths & Weaknesses

8.11 Aurigene Pharmaceutical Services

8.11.1 Aurigene Pharmaceutical Services Details

8.11.2 Aurigene Pharmaceutical Services Major Business

8.11.3 Aurigene Pharmaceutical Services CDMO Service for Peptide APIs Product and Services

8.11.4 Aurigene Pharmaceutical Services CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.11.5 Aurigene Pharmaceutical Services Recent Developments/Updates

8.11.6 Aurigene Pharmaceutical Services Competitive Strengths & Weaknesses

8.12 PeptiStar

8.12.1 PeptiStar Details

8.12.2 PeptiStar Major Business

8.12.3 PeptiStar CDMO Service for Peptide APIs Product and Services

8.12.4 PeptiStar CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

- 8.12.5 PeptiStar Recent Developments/Updates
- 8.12.6 PeptiStar Competitive Strengths & Weaknesses
- 8.13 BCN Peptides
 - 8.13.1 BCN Peptides Details
 - 8.13.2 BCN Peptides Major Business
 - 8.13.3 BCN Peptides CDMO Service for Peptide APIs Product and Services
 - 8.13.4 BCN Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.13.5 BCN Peptides Recent Developments/Updates
 - 8.13.6 BCN Peptides Competitive Strengths & Weaknesses
- 8.14 Creative Peptides
 - 8.14.1 Creative Peptides Details
 - 8.14.2 Creative Peptides Major Business
 - 8.14.3 Creative Peptides CDMO Service for Peptide APIs Product and Services
 - 8.14.4 Creative Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.14.5 Creative Peptides Recent Developments/Updates
 - 8.14.6 Creative Peptides Competitive Strengths & Weaknesses
- 8.15 Space Peptides
 - 8.15.1 Space Peptides Details
 - 8.15.2 Space Peptides Major Business
 - 8.15.3 Space Peptides CDMO Service for Peptide APIs Product and Services
 - 8.15.4 Space Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.15.5 Space Peptides Recent Developments/Updates
 - 8.15.6 Space Peptides Competitive Strengths & Weaknesses
- 8.16 Cambrex
 - 8.16.1 Cambrex Details
 - 8.16.2 Cambrex Major Business
 - 8.16.3 Cambrex CDMO Service for Peptide APIs Product and Services
 - 8.16.4 Cambrex CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
 - 8.16.5 Cambrex Recent Developments/Updates
 - 8.16.6 Cambrex Competitive Strengths & Weaknesses
- 8.17 Nippon Shokubai
 - 8.17.1 Nippon Shokubai Details
 - 8.17.2 Nippon Shokubai Major Business
 - 8.17.3 Nippon Shokubai CDMO Service for Peptide APIs Product and Services
 - 8.17.4 Nippon Shokubai CDMO Service for Peptide APIs Revenue, Gross Margin and

Market Share (2021-2026)

8.17.5 Nippon Shokubai Recent Developments/Updates

8.17.6 Nippon Shokubai Competitive Strengths & Weaknesses

8.18 ScinoPharm

8.18.1 ScinoPharm Details

8.18.2 ScinoPharm Major Business

8.18.3 ScinoPharm CDMO Service for Peptide APIs Product and Services

8.18.4 ScinoPharm CDMO Service for Peptide APIs Revenue, Gross Margin and

Market Share (2021-2026)

8.18.5 ScinoPharm Recent Developments/Updates

8.18.6 ScinoPharm Competitive Strengths & Weaknesses

8.19 ChengDu ShengNuo Biotec

8.19.1 ChengDu ShengNuo Biotec Details

8.19.2 ChengDu ShengNuo Biotec Major Business

8.19.3 ChengDu ShengNuo Biotec CDMO Service for Peptide APIs Product and Services

8.19.4 ChengDu ShengNuo Biotec CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.19.5 ChengDu ShengNuo Biotec Recent Developments/Updates

8.19.6 ChengDu ShengNuo Biotec Competitive Strengths & Weaknesses

8.20 WuXi TIDES

8.20.1 WuXi TIDES Details

8.20.2 WuXi TIDES Major Business

8.20.3 WuXi TIDES CDMO Service for Peptide APIs Product and Services

8.20.4 WuXi TIDES CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.20.5 WuXi TIDES Recent Developments/Updates

8.20.6 WuXi TIDES Competitive Strengths & Weaknesses

8.21 Asymchem

8.21.1 Asymchem Details

8.21.2 Asymchem Major Business

8.21.3 Asymchem CDMO Service for Peptide APIs Product and Services

8.21.4 Asymchem CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)

8.21.5 Asymchem Recent Developments/Updates

8.21.6 Asymchem Competitive Strengths & Weaknesses

8.22 Medtide

8.22.1 Medtide Details

8.22.2 Medtide Major Business

- 8.22.3 Medtide CDMO Service for Peptide APIs Product and Services
- 8.22.4 Medtide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
- 8.22.5 Medtide Recent Developments/Updates
- 8.22.6 Medtide Competitive Strengths & Weaknesses
- 8.23 Jiuzhou Pharma
- 8.23.1 Jiuzhou Pharma Details
- 8.23.2 Jiuzhou Pharma Major Business
- 8.23.3 Jiuzhou Pharma CDMO Service for Peptide APIs Product and Services
- 8.23.4 Jiuzhou Pharma CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
- 8.23.5 Jiuzhou Pharma Recent Developments/Updates
- 8.23.6 Jiuzhou Pharma Competitive Strengths & Weaknesses
- 8.24 Hybio Pharmaceutical
- 8.24.1 Hybio Pharmaceutical Details
- 8.24.2 Hybio Pharmaceutical Major Business
- 8.24.3 Hybio Pharmaceutical CDMO Service for Peptide APIs Product and Services
- 8.24.4 Hybio Pharmaceutical CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
- 8.24.5 Hybio Pharmaceutical Recent Developments/Updates
- 8.24.6 Hybio Pharmaceutical Competitive Strengths & Weaknesses
- 8.25 JYMed Peptide
- 8.25.1 JYMed Peptide Details
- 8.25.2 JYMed Peptide Major Business
- 8.25.3 JYMed Peptide CDMO Service for Peptide APIs Product and Services
- 8.25.4 JYMed Peptide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026)
- 8.25.5 JYMed Peptide Recent Developments/Updates
- 8.25.6 JYMed Peptide Competitive Strengths & Weaknesses

9 INDUSTRY CHAIN ANALYSIS

- 9.1 CDMO Service for Peptide APIs Industry Chain
- 9.2 CDMO Service for Peptide APIs Upstream Analysis
- 9.3 CDMO Service for Peptide APIs Midstream Analysis
- 9.4 CDMO Service for Peptide APIs Downstream Analysis

10 RESEARCH FINDINGS AND CONCLUSION

11 APPENDIX

11.1 Methodology

11.2 Research Process and Data Source

11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World CDMO Service for Peptide APIs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World CDMO Service for Peptide APIs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World CDMO Service for Peptide APIs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World CDMO Service for Peptide APIs Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World CDMO Service for Peptide APIs Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World CDMO Service for Peptide APIs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World CDMO Service for Peptide APIs Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World CDMO Service for Peptide APIs Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World CDMO Service for Peptide APIs Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key CDMO Service for Peptide APIs Players in 2025

Table 12. World CDMO Service for Peptide APIs Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global CDMO Service for Peptide APIs Company Evaluation Quadrant

Table 14. Head Office of Key CDMO Service for Peptide APIs Players

Table 15. CDMO Service for Peptide APIs Market: Company Product Type Footprint

Table 16. CDMO Service for Peptide APIs Market: Company Product Application Footprint

Table 17. CDMO Service for Peptide APIs Mergers & Acquisitions Activity

Table 18. United States VS China CDMO Service for Peptide APIs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China CDMO Service for Peptide APIs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based CDMO Service for Peptide APIs Companies, Headquarters (States, Country)

Table 21. United States Based Companies CDMO Service for Peptide APIs Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies CDMO Service for Peptide APIs Revenue Market Share (2021-2026)

Table 23. China Based CDMO Service for Peptide APIs Companies, Headquarters (Province, Country)

Table 24. China Based Companies CDMO Service for Peptide APIs Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies CDMO Service for Peptide APIs Revenue Market Share (2021-2026)

Table 26. Rest of World Based CDMO Service for Peptide APIs Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies CDMO Service for Peptide APIs Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies CDMO Service for Peptide APIs Revenue Market Share (2021-2026)

Table 29. World CDMO Service for Peptide APIs Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World CDMO Service for Peptide APIs Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World CDMO Service for Peptide APIs Market Size by Type (2027-2032) & (USD Million)

Table 32. World CDMO Service for Peptide APIs Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032

Table 33. World CDMO Service for Peptide APIs Market Size Value by Synthesis Technology (2021-2026) & (USD Million)

Table 34. World CDMO Service for Peptide APIs Market Size by Synthesis Technology (2027-2032) & (USD Million)

Table 35. World CDMO Service for Peptide APIs Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 36. World CDMO Service for Peptide APIs Market Size by Application (2021-2026) & (USD Million)

Table 37. World CDMO Service for Peptide APIs Market Size by Application (2027-2032) & (USD Million)

Table 38. PolyPeptide Basic Information, Manufacturing Base and Competitors

Table 39. PolyPeptide Major Business

Table 40. PolyPeptide CDMO Service for Peptide APIs Product and Services

Table 41. PolyPeptide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 42. PolyPeptide Recent Developments/Updates
Table 43. PolyPeptide Competitive Strengths & Weaknesses
Table 44. Bachem Basic Information, Manufacturing Base and Competitors
Table 45. Bachem Major Business
Table 46. Bachem CDMO Service for Peptide APIs Product and Services
Table 47. Bachem CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Bachem Recent Developments/Updates
Table 49. Bachem Competitive Strengths & Weaknesses
Table 50. AmbioPharm Basic Information, Manufacturing Base and Competitors
Table 51. AmbioPharm Major Business
Table 52. AmbioPharm CDMO Service for Peptide APIs Product and Services
Table 53. AmbioPharm CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. AmbioPharm Recent Developments/Updates
Table 55. AmbioPharm Competitive Strengths & Weaknesses
Table 56. CordenPharma Basic Information, Manufacturing Base and Competitors
Table 57. CordenPharma Major Business
Table 58. CordenPharma CDMO Service for Peptide APIs Product and Services
Table 59. CordenPharma CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. CordenPharma Recent Developments/Updates
Table 61. CordenPharma Competitive Strengths & Weaknesses
Table 62. CPC Scientific Basic Information, Manufacturing Base and Competitors
Table 63. CPC Scientific Major Business
Table 64. CPC Scientific CDMO Service for Peptide APIs Product and Services
Table 65. CPC Scientific CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. CPC Scientific Recent Developments/Updates
Table 67. CPC Scientific Competitive Strengths & Weaknesses
Table 68. Piramal Pharma Solutions Basic Information, Manufacturing Base and Competitors
Table 69. Piramal Pharma Solutions Major Business
Table 70. Piramal Pharma Solutions CDMO Service for Peptide APIs Product and Services
Table 71. Piramal Pharma Solutions CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Piramal Pharma Solutions Recent Developments/Updates
Table 73. Piramal Pharma Solutions Competitive Strengths & Weaknesses

Table 74. Almac Group Basic Information, Manufacturing Base and Competitors

Table 75. Almac Group Major Business

Table 76. Almac Group CDMO Service for Peptide APIs Product and Services

Table 77. Almac Group CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 78. Almac Group Recent Developments/Updates

Table 79. Almac Group Competitive Strengths & Weaknesses

Table 80. Aspen API Basic Information, Manufacturing Base and Competitors

Table 81. Aspen API Major Business

Table 82. Aspen API CDMO Service for Peptide APIs Product and Services

Table 83. Aspen API CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 84. Aspen API Recent Developments/Updates

Table 85. Aspen API Competitive Strengths & Weaknesses

Table 86. Neuland Laboratories Basic Information, Manufacturing Base and Competitors

Table 87. Neuland Laboratories Major Business

Table 88. Neuland Laboratories CDMO Service for Peptide APIs Product and Services

Table 89. Neuland Laboratories CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 90. Neuland Laboratories Recent Developments/Updates

Table 91. Neuland Laboratories Competitive Strengths & Weaknesses

Table 92. USV Basic Information, Manufacturing Base and Competitors

Table 93. USV Major Business

Table 94. USV CDMO Service for Peptide APIs Product and Services

Table 95. USV CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 96. USV Recent Developments/Updates

Table 97. USV Competitive Strengths & Weaknesses

Table 98. Aurigene Pharmaceutical Services Basic Information, Manufacturing Base and Competitors

Table 99. Aurigene Pharmaceutical Services Major Business

Table 100. Aurigene Pharmaceutical Services CDMO Service for Peptide APIs Product and Services

Table 101. Aurigene Pharmaceutical Services CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 102. Aurigene Pharmaceutical Services Recent Developments/Updates

Table 103. Aurigene Pharmaceutical Services Competitive Strengths & Weaknesses

Table 104. PeptiStar Basic Information, Manufacturing Base and Competitors

Table 105. PeptiStar Major Business
Table 106. PeptiStar CDMO Service for Peptide APIs Product and Services
Table 107. PeptiStar CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. PeptiStar Recent Developments/Updates
Table 109. PeptiStar Competitive Strengths & Weaknesses
Table 110. BCN Peptides Basic Information, Manufacturing Base and Competitors
Table 111. BCN Peptides Major Business
Table 112. BCN Peptides CDMO Service for Peptide APIs Product and Services
Table 113. BCN Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. BCN Peptides Recent Developments/Updates
Table 115. BCN Peptides Competitive Strengths & Weaknesses
Table 116. Creative Peptides Basic Information, Manufacturing Base and Competitors
Table 117. Creative Peptides Major Business
Table 118. Creative Peptides CDMO Service for Peptide APIs Product and Services
Table 119. Creative Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Creative Peptides Recent Developments/Updates
Table 121. Creative Peptides Competitive Strengths & Weaknesses
Table 122. Space Peptides Basic Information, Manufacturing Base and Competitors
Table 123. Space Peptides Major Business
Table 124. Space Peptides CDMO Service for Peptide APIs Product and Services
Table 125. Space Peptides CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. Space Peptides Recent Developments/Updates
Table 127. Space Peptides Competitive Strengths & Weaknesses
Table 128. Cambrex Basic Information, Manufacturing Base and Competitors
Table 129. Cambrex Major Business
Table 130. Cambrex CDMO Service for Peptide APIs Product and Services
Table 131. Cambrex CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Cambrex Recent Developments/Updates
Table 133. Cambrex Competitive Strengths & Weaknesses
Table 134. Nippon Shokubai Basic Information, Manufacturing Base and Competitors
Table 135. Nippon Shokubai Major Business
Table 136. Nippon Shokubai CDMO Service for Peptide APIs Product and Services
Table 137. Nippon Shokubai CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 138. Nippon Shokubai Recent Developments/Updates
Table 139. Nippon Shokubai Competitive Strengths & Weaknesses
Table 140. ScinoPharm Basic Information, Manufacturing Base and Competitors
Table 141. ScinoPharm Major Business
Table 142. ScinoPharm CDMO Service for Peptide APIs Product and Services
Table 143. ScinoPharm CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 144. ScinoPharm Recent Developments/Updates
Table 145. ScinoPharm Competitive Strengths & Weaknesses
Table 146. ChengDu ShengNuo Biotec Basic Information, Manufacturing Base and Competitors
Table 147. ChengDu ShengNuo Biotec Major Business
Table 148. ChengDu ShengNuo Biotec CDMO Service for Peptide APIs Product and Services
Table 149. ChengDu ShengNuo Biotec CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 150. ChengDu ShengNuo Biotec Recent Developments/Updates
Table 151. ChengDu ShengNuo Biotec Competitive Strengths & Weaknesses
Table 152. WuXi TIDES Basic Information, Manufacturing Base and Competitors
Table 153. WuXi TIDES Major Business
Table 154. WuXi TIDES CDMO Service for Peptide APIs Product and Services
Table 155. WuXi TIDES CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 156. WuXi TIDES Recent Developments/Updates
Table 157. WuXi TIDES Competitive Strengths & Weaknesses
Table 158. Asymchem Basic Information, Manufacturing Base and Competitors
Table 159. Asymchem Major Business
Table 160. Asymchem CDMO Service for Peptide APIs Product and Services
Table 161. Asymchem CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 162. Asymchem Recent Developments/Updates
Table 163. Asymchem Competitive Strengths & Weaknesses
Table 164. Medtide Basic Information, Manufacturing Base and Competitors
Table 165. Medtide Major Business
Table 166. Medtide CDMO Service for Peptide APIs Product and Services
Table 167. Medtide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 168. Medtide Recent Developments/Updates
Table 169. Medtide Competitive Strengths & Weaknesses

Table 170. Jiuzhou Pharma Basic Information, Manufacturing Base and Competitors

Table 171. Jiuzhou Pharma Major Business

Table 172. Jiuzhou Pharma CDMO Service for Peptide APIs Product and Services

Table 173. Jiuzhou Pharma CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 174. Jiuzhou Pharma Recent Developments/Updates

Table 175. Jiuzhou Pharma Competitive Strengths & Weaknesses

Table 176. Hybio Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 177. Hybio Pharmaceutical Major Business

Table 178. Hybio Pharmaceutical CDMO Service for Peptide APIs Product and Services

Table 179. Hybio Pharmaceutical CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 180. Hybio Pharmaceutical Recent Developments/Updates

Table 181. Hybio Pharmaceutical Competitive Strengths & Weaknesses

Table 182. JYMed Peptide Basic Information, Manufacturing Base and Competitors

Table 183. JYMed Peptide Major Business

Table 184. JYMed Peptide CDMO Service for Peptide APIs Product and Services

Table 185. JYMed Peptide CDMO Service for Peptide APIs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 186. JYMed Peptide Recent Developments/Updates

Table 187. JYMed Peptide Competitive Strengths & Weaknesses

Table 188. Global Key Players of CDMO Service for Peptide APIs Upstream (Raw Materials)

Table 189. Global CDMO Service for Peptide APIs Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. CDMO Service for Peptide APIs Picture

Figure 2. World CDMO Service for Peptide APIs Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World CDMO Service for Peptide APIs Total Revenue (2021-2032) & (USD Million)

Figure 4. World CDMO Service for Peptide APIs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World CDMO Service for Peptide APIs Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company CDMO Service for Peptide APIs Revenue (2021-2032) & (USD Million)

Figure 13. CDMO Service for Peptide APIs Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 16. World CDMO Service for Peptide APIs Consumption Value Market Share by Region (2021-2032)

Figure 17. United States CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 18. China CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 23. India CDMO Service for Peptide APIs Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of CDMO Service for Peptide APIs by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for CDMO Service for Peptide APIs Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for CDMO Service for Peptide APIs Markets in 2025

Figure 27. United States VS China: CDMO Service for Peptide APIs Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: CDMO Service for Peptide APIs Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World CDMO Service for Peptide APIs Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World CDMO Service for Peptide APIs Market Size Market Share by Type in 2025

Figure 31. GMP Services

Figure 32. Non-GMP Services

Figure 33. World CDMO Service for Peptide APIs Market Size Market Share by Type (2021-2032)

Figure 34. World CDMO Service for Peptide APIs Market Size by Synthesis Technology, (USD Million), 2021 & 2025 & 2032

Figure 35. World CDMO Service for Peptide APIs Market Size Market Share by Synthesis Technology in 2025

Figure 36. SPPS

Figure 37. LPPS

Figure 38. Hybrid Technology

Figure 39. World CDMO Service for Peptide APIs Market Size Market Share by Synthesis Technology (2021-2032)

Figure 40. World CDMO Service for Peptide APIs Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 41. World CDMO Service for Peptide APIs Market Size Market Share by Application in 2025

Figure 42. Pharmaceutical Companies

Figure 43. Biotechnology Companies

Figure 44. Academic and Research Institutions

Figure 45. Others

Figure 46. World CDMO Service for Peptide APIs Market Size Market Share by Application (2021-2032)

Figure 47. CDMO Service for Peptide APIs Industrial Chain

Figure 48. Methodology

Figure 49. Research Process and Data Source

I would like to order

Product name: Global CDMO Service for Peptide APIs Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G990641EC9C2EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G990641EC9C2EN.html>